SAN DIEGO, Jan. 6, 2016 /PRNewswire/ -- ViaCyte, Inc., a privately-held regenerative medicine company with the first pluripotent stem cell-derived islet replacement therapy for the treatment of diabetes in clinical-stage development, today announced a company presentation at Biotech ShowcaseTM 2016, which will take place in San Francisco, January 11 to 13, 2016.
Details of the presentation are as follows:
|
Title: |
Preclinical and Clinical Testing of VC-01 Product Candidate: Stem Cell-Derived, Macroencapsulated Islet Cell Replacement for Type 1 Diabetes |
|
Speaker: |
Dr. Paul Laikind, President and Chief Executive Officer |
|
Date/Time: |
January 11, 11:00 a.m. PST |
|
Location: |
Room Davidson, Parc 55 San Francisco |
To register for the event or for more information, please visit Biotech Showcase's website: http://www.ebdgroup.com/bts/program/index.php.
ViaCyte's VC-01™ product candidate, a first-in-class cell replacement therapy for the treatment of type 1 diabetes, is currently being evaluated in a Phase 1/2 trial called STEP ONE, or Safety, Tolerability, and Efficacy of VC-01 Combination Product in Type One Diabetes. More information on the clinical trial is here: https://clinicaltrials.gov/ct2/show/NCT02239354.
Dr. Laikind will present both an update on the STEP ONE trial as well as discuss a second product candidate in development, called PEC-DirectTM, for patients with type 1 diabetes who are at high risk for complications associated with conventional treatment, or who have undergone a kidney transplant. PEC-Direct involves implantation of pancreatic progenitor cells in a manner enabling more direct access by vasculature. This approach is similar to the use of cadaver islet cell transplants, which have proven effective for patients at high risk but have been limited by availability of donor organs. As with the current islet cell transplant procedure and other organ transplants, patients receiving PEC-Direct would require chronic immunosuppression to prevent rejection.
"As many as 5 to 10 percent of patients with type 1 diabetes are at high risk of severe complications resulting from the management of their disease," said Dr. Laikind. "We have been developing PEC-Direct as a way to bring a much-needed new therapy to help these patients."
For more information about ViaCyte's participation in industry events, please visit: http://viacyte.com/news-events-2/viactye-events/
About ViaCyte:
ViaCyte is a privately-held regenerative medicine company focused on developing novel cell replacement therapies for the treatment of diabetes. ViaCyte is conducting a Phase 1/2 clinical trial of the Company's lead VC-01 product candidate in patients with type 1 diabetes who have minimal to no insulin-producing beta cell function. ViaCyte's VC-01 combination product candidate is based on the production of pancreatic progenitor cells derived from human pluripotent stem cells. These progenitor cells are implanted in a durable and retrievable encapsulation device. Once implanted and matured, these cells are designed to secrete insulin and other regulatory factors in response to blood glucose levels. The VC-01 product candidate is being developed as a potential long-term diabetes treatment with the goals of no immune suppression required, and a reduced risk of hypoglycemia and diabetes-related complications. PEC-Direct utilizes the same cells as VC-01 contained in a device that allows direct vasculature access but does not provide immune protection.
ViaCyte is headquartered in San Diego, California with additional operations in Athens, Georgia. The Company is funded in part by the California Institute for Regenerative Medicine (CIRM) and JDRF.
For more information please visit www.viacyte.com. Connect with ViaCyte here: www.twitter.com/viacyte and www.facebook.com/viacyte.
Logo - http://photos.prnewswire.com/prnh/20121026/LA00871LOGO-a
SOURCE ViaCyte, Inc.